Literature DB >> 22644722

Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.

Giuseppe Lippi1, Emmanuel J Favaloro, Massimo Franchini.   

Abstract

The pathogenesis of venous and arterial thrombosis is complex and multifaceted, entailing a multitude of risk factors, which only marginally overlap between the two vessels districts. Along with conventional and universally recognized risk factors, thrombosis might also develop as a consequence of unusual, atypical, unsuspected and even paradoxical conditions. Although the term "paradoxical embolism" is typically used to identify an embolization process that originates from the low-pressure venous system and may generate ischemic stroke or peripheral arterial occlusion through a cardiac or pulmonary shunt, there are additional clinical circumstances whereby the risk of thrombosis is surprising, unpredicted or even neglected. In this article we thereby analyze the prevalence, as well as the pathogenesis, of thrombosis associated with apparently paradoxical triggers such as during factor replacement therapy in haemophiliacs or in patients with von Willebrand disease; in patients with inherited clotting factor deficiencies especially involving factor XII, factor VII, fibrinogen; or in those with a prolonged activated partial thromboplastin time for the presence of lupus anticoagulant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644722     DOI: 10.1007/s11239-012-0753-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  62 in total

Review 1.  Deep venous thrombosis in hemophilia A.

Authors:  B Ritchie; R C Woodman; M C Poon
Journal:  Am J Med       Date:  1992-12       Impact factor: 4.965

Review 2.  Interpretation and recommended testing for antiphospholipid antibodies.

Authors:  Monica Galli
Journal:  Semin Thromb Hemost       Date:  2012-03-07       Impact factor: 4.180

Review 3.  Acquired inhibitors of coagulation factors: part II.

Authors:  Massimo Franchini; Giuseppe Lippi; Emmanuel J Favaloro
Journal:  Semin Thromb Hemost       Date:  2012-06-27       Impact factor: 4.180

Review 4.  Arterial thrombus formation in cardiovascular disease.

Authors:  Giuseppe Lippi; Massimo Franchini; Giovanni Targher
Journal:  Nat Rev Cardiol       Date:  2011-07-05       Impact factor: 32.419

5.  Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII.

Authors:  Carine J M Doggen; Frits R Rosendaal; Joost C M Meijers
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

Review 6.  Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.

Authors:  Alfonso Iorio; Davide Matino; Roberto D'Amico; Michael Makris
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

7.  Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.

Authors:  Pier M Mannucci; Juan Chediak; Wahid Hanna; John Byrnes; Marlies Ledford; Bruce M Ewenstein; Anastassios D Retzios; Barbara A Kapelan; Richard S Schwartz; Craig Kessler
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

Review 8.  Thrombotic complications in patients with hereditary bleeding disorders.

Authors:  Massimo Franchini
Journal:  Thromb Haemost       Date:  2004-08       Impact factor: 5.249

Review 9.  The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature.

Authors:  A Girolami; M L Randi; S Gavasso; A M Lombardi; F Spiezia
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

10.  Thrombosis in inherited factor VII deficiency.

Authors:  G Mariani; F H Herrmann; S Schulman; A Batorova; K Wulff; D Etro; A Dolce; G Auerswald; J Astermark; J-F Schved; J Ingerslev; F Bernardi
Journal:  J Thromb Haemost       Date:  2003-10       Impact factor: 5.824

View more
  2 in total

Review 1.  Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

2.  Risk Factors for Pulmonary Embolism in ICU Patients: A Retrospective Cohort Study from the MIMIC-III Database.

Authors:  Cheng-Bin Huang; Chen-Xuan Hong; Tian-Hao Xu; Ding-Yun Zhao; Zong-Yi Wu; Liang Chen; Jun Xie; Chen Jin; Bing-Zhang Wang; Lei Yang
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.